DALLAS, July 2, 2015 /PRNewswire/ --
LifeScienceIndustryResearch.com adds Personalized Medicine, Targeted Therapeutics & Companion Diagnostic Market to 2019 research report published in July 2015 to the pharmaceuticals intelligence collection of its library.
Complete report on personalized medicine market spread across 279 pages, talking about 15 major companies and supported with 317 tables and figures is now available at http://www.lifescienceindustryresearch.com/personalized-medicine-targeted-therapeutics-companion-diagnostic-market-to-2019.html .
Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market - A Strategic Analysis of Industry Trends, Technologies, Participants, and Environment to 2019 research report provides a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The global personalized medicine market is presented by company (e.g., Qiagen, Affymetrix, Atossa Genetics, Nodality, Celera, Myriad), by geography (US, UK, Global), by segment (Targeted therapeutics, Companion Diagnostics), by sub-market (Companion diagnostic, targeted cancer therapeutic, medical technology, pharmacogenomics, consumer
genomics, molecular diagnostics) and by therapy (Cancer, Cardiovascular, Infectious Disease).
This report tackles key concerns to the personalized medicine market such as lack of regulatory policy and legislation in the US and Europe, reimbursement schemes and payers concerns, transition of investigational diagnostic assays and therapeutics to clinical practice and direct to consumer (DTC) test kits and implications for the public. This research provides an in-depth understanding of the global personalized medicine market and its environment with current market facts, figures and product lines of key players in the industry. Emerging trends in key markets such as the US, UK, Germany and France are covered along with knowledge of how the personalized medicine market will integrate into the global healthcare market. Technical insights into new generation sequencing technologies and ultra-high throughput sequencing are a part of this research supported with updates on bioinformatics, high throughput systems, genetic analysis kits, companion diagnostics and future technologies. FDA approved pharmacogenetic tests and recognized biomarkers, information on key government and regulatory policies as well as strategies on how to adapt and restructure current business models to this industry are also discussed.
This personalized medicine market 2015 research highlights a number of significant pharmacos and gives details of their operations, products, financials and business strategy. Companies discussed include 23andMe, Affymetrix, Astex Pharmaceuticals, Atossa Genetics, CuraGen, Celera Corporation (Quest Diagnostics), Celldex Therapeutics, deCode Genetics (Amgen), Illumina, Genelex, Myriad, Nodality, Qiagen, Admera Health (GeneWiz) and Claritas Genomics. Order a copy of Personalized Medicine, Targeted Therapeutics & Companion Diagnostic Market to 2019 research report at http://www.lifescienceindustryresearch.com/purchase?rname=44597 .
SWOT, Economic & Regulatory Environment specifics included in this personalized medicine market report include key strengths, weaknesses and threats influencing leading player position within the market; Technologies driving the market (e.g., New-Generation Sequencing Technologies, Ultra-High Throughput Sequencing); Top fastest growing market segments and emerging opportunities; Top pharmaceutical companies within the IPM by market share and revenue; Comprehensive product portfolios, R&D activity and pipeline therapeutics; M&A activity and future strategies of top personalized medicine pharmacos; Personalized Medicine Regulation (UK, Germany, France, Spain, Italy); CE-marked Personalized Medicine/Diagnostic Tests and FDA Advances in Personalized Medicine Regulation.
This 2015 personalized medicine market report is beneficial for pharmaceutical, biotechnology and diagnostic companies with an interest in personalized medicine, industry professionals and business strategists will discover key information to propel their policies, investors will gain inside information to dominant players in the industry and future forecasts and scientists will get a business perspective and industry insight into how scientific breakthroughs influence the market environment.
On a related note, the Personalized Medicine Partnering Terms and Agreements market research report provides comprehensive understanding and unprecedented access to the personalized medicine partnering deals and agreements entered into by the world's leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter personalized medicine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors personalized medicine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report contains over 1000 links to online copies of actual personalized medicine deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. In addition, a comprehensive appendix is provided organized by personalized medicine partnering company A-Z , deal type, and therapy type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Comprehensive Table of Contents and more on the personalized medicine partnering terms and agreements report is available at http://www.lifescienceindustryresearch.com/personalized-medicine-partnering-terms-and-agreements.html .
A third research, titled Deals in Oncology Personalized Medicine Industry - Worldwide Analysis is a report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the world's leading healthcare companies in oncology sector. All the deals have been tracked year wise. All the deals have been covered under different chapters in below mentioned topics.
- Collaboration Deals (Chapter No. 2.1)
- Partnership Deals (Chapter No. 2.2)
- Distribution Agreement Deals (Chapter No. 2.3)
- Joint Venture Deals (Chapter No. 2.4)
- Licensing Agreement Deals (Chapter No. 2.5)
- Strategic Alliances Deals (Chapter No. 2.6)
- Merger & Acquisition Deals (Chapter No. 2.7)
- Co-Promotion Deals (Chapter No. 2.8)
- Co-Marketing Deals (Chapter No. 2.9)
- Co-Development Deals (Chapter No. 2.10)
Complete report is available at http://www.lifescienceindustryresearch.com/deals-in-oncology-personalized-medicine-industry-worldwide-analysis.html .
Explore more reports on the pharmaceuticals market at http://www.lifescienceindustryresearch.com/category/pharmaceuticals .
About Us:
Life Science Industry Researchbrings to you to the latest reports in market research on Biotechnology, Diagnostics, Healthcare, Medical Devices and Pharmaceuticals segments from leading research publishers across the globe. These reports also cover data and information on sub-segments and sectors under these life sciences categories.
Connect with Us:
G+ / Google Plus: https://plus.google.com/112612135957880308475/about
Twitter: https://twitter.com/LifeSciReports
RSS / Feeds: http://www.lifescienceindustryresearch.com/feed
Contact:
Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel: +1-888-391-5441
sales@lifescienceindustryresearch.com
